Noticeably Tregs from TDLNs can express COX-2 by which they suppress IFN-γ as well TNF-α production of peripheral T cells; thus providing an additional argument in favor of COX-2 inhibition in CRC patients [48]. This evidence concerns the gene PTGS2 and colorectal carcinoma.